The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support
Open accessAbstract
Objectives Heart failure (HF) is characterized by perturbations in energy homeostasis and metabolism. The reversibility and prognostic value of circulating markers reporting on these changes remain unclear. We sought to describe the metabolomic profiles of patients along the spectrum of systolic HF, determine their association with adverse outcomes in a clinical trial of HF, and evaluate whether identified metabolites change with treatment for end-stage systolic HF. Methods To assess association of metabolites with clinical outcomes, a population of 453 chronic systolic HF patients who participated in the HF-ACTION trial, which randomized ambulatory, stable patients to exercise training versus usual care, were included. To assess change in metabolites with mechanical circulatory support, 41 patients with end-stage HF who underwent left ventricular assist device (LVAD) placement were studied. Targeted, quantitative profiling of 60 metabolites using tandem flow injection mass spectrometry was performed on frozen plasma samples obtained prior to randomization in the HF-ACTION group, as well as, prior to and ≥90 days post placement in the LVAD group. Principal components analysis (PCA) was used for data reduction; linear regression and Cox-proportional hazards regression modeling were used to assess the relation between the PCA-derived metabolite factor levels and clinical outcomes among patients from the HF-ACTION study. Differences between metabolite factors associated with outcomes in the HF-ACTION and LVAD groups were assessed using Wilcoxon rank sum tests. Results Five PCA-derived factors were significantly associated with peak VO2 levels at baseline in fully adjusted models. Of these, Factor 5 (composed of long-chain acylcarnitines) was associated with increased risk of all 3 pre-specified HF-ACTION clinical outcomes: all-cause mortality/all-cause hospitalization (HR: 1.24; 95% CI 1.09–1.42), all cause-hospitalization (HR: 1.42; 95% CI 1.16–1.74), and cardiovascular death or cardiovascular hospitalization (HR: 1.22; CI 1.06–1.39). Individual components of Factor 5 (C16, C18:1, and C18:2 acylcarnitine metabolites) were significantly higher in patients with end-stage HF prior to LVAD placement and decreased significantly after LVAD therapy. Conclusions In chronic HF patients, circulating long chain acylcarnitine metabolite levels were independently associated with clinical outcomes and decreased after long-term mechanical circulatory support. These metabolites, which report on mitochondrial fatty acid β-oxidation, highlight pathways that may serve as potential targets for new diagnostics or therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Human Hypertension
Lifton, R. P., Gharavi, A. G., & Geller, D. S. (2001) · Cell · doi:10.1016/s0092-8674(01)00241-0 · Cited by 1,686
Disorders of carnitine transport and the carnitine cycle
Longo, N., Amat di San Filippo, C., & Pasquali, M. (2006) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30087 · Cited by 543
Cited by
Comprehensive quantification of fuel use by the failing and nonfailing human heart
Murashige, D., Jang, C., Neinast, M., Edwards, J. J., Cowan, A., Hyman, M. C., Rabinowitz, J. D., Frankel, D. S., & Arany, Z. (2020) · Science · doi:10.1126/science.abc8861 · Cited by 580
Biomarkers for the diagnosis and management of heart failure
Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10105-w · Cited by 512
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
McGarrah, R. W., Crown, S. B., Zhang, G.-F., Shah, S. H., & Newgard, C. B. (2018) · Circulation Research · doi:10.1161/circresaha.117.311002 · Cited by 423
Self-citationThe Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease
Ussher, J. R., Elmariah, S., Gerszten, R. E., & Dyck, J. R. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.972 · Cited by 358
Metadata
- Authors
- Ahmad, T., Kelly, J. P., McGarrah, R. W., Hellkamp, A. S., Fiuzat, M., Testani, J. M., Wang, T. S., Verma, A., Samsky, M. D., Donahue, M. P., Ilkayeva, O. R., Bowles, D. E., Patel, C. B., Milano, C. A., Rogers, J. G., Felker, G. M., O’Connor, C. M., Shah, S. H., & Kraus, W. E.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 67
- Issue
- 3
- Pages
- 291-299
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2278098643
- Cited by
- 214
- References
- 2
- FWCI
- 12.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. https://app.cochat.ai/papers/10.1016/j.jacc.2015.10.079
- The paper
- Ahmad, T., Kelly, J. P., McGarrah, R. W., Hellkamp, A. S., Fiuzat, M., Testani, J. M., Wang, T. S., Verma, A., Samsky, M. D., Donahue, M. P., Ilkayeva, O. R., Bowles, D. E., Patel, C. B., Milano, C. A., Rogers, J. G., Felker, G. M., O’Connor, C. M., Shah, S. H., & Kraus, W. E. (2016). Prognostic Implications of Long-Chain Acylcarnitines in Heart Failure and Reversibility With Mechanical Circulatory Support. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2015.10.079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.